Merck KGaA (FRA:MRK) has been assigned a €115.00 ($136.90) price objective by stock analysts at Sanford C. Bernstein in a research note issued on Wednesday, November 15th. The brokerage presently has a “buy” rating on the healthcare company’s stock. Sanford C. Bernstein’s price objective would suggest a potential upside of 28.03% from the company’s current price.
A number of other research firms have also weighed in on MRK. Kepler Capital Markets set a €115.00 ($136.90) target price on Merck KGaA and gave the company a “buy” rating in a report on Monday, November 6th. Warburg Research set a €115.00 ($136.90) price target on Merck KGaA and gave the stock a “buy” rating in a report on Thursday, November 9th. Independent Research set a €103.00 ($122.62) price target on Merck KGaA and gave the stock a “neutral” rating in a report on Thursday, November 9th. Berenberg Bank set a €116.00 ($138.10) price target on Merck KGaA and gave the stock a “buy” rating in a report on Thursday, November 9th. Finally, Commerzbank set a €103.00 ($122.62) price target on Merck KGaA and gave the stock a “neutral” rating in a report on Thursday, November 9th. Eleven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of €108.52 ($129.20).
Merck KGaA (FRA MRK) traded up €0.43 ($0.51) during mid-day trading on Wednesday, hitting €89.82 ($106.93). The stock had a trading volume of 559,648 shares. Merck KGaA has a 52 week low of €87.99 ($104.75) and a 52 week high of €115.00 ($136.90).
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.